The Cooper Companies, Inc. (COO) vs 10x Genomics, Inc. (TXG)
A side-by-side comparison of The Cooper Companies, Inc. and 10x Genomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
COO
The Cooper Companies, Inc.
$56.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TXG
10x Genomics, Inc.
$80.66HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — COO vs TXG
growth of $100 · dividends reinvested · last 7yCOO -24.8% (-4.0%/yr)TXG +85.3% (+9.2%/yr)TXG compounded faster over this window
COO TXG
COO vs TXG: by the numbers
- •COO is the larger company ($11.01B vs $10.24B market cap).
- •COO is profitable (13.46% net margin) while TXG runs a net loss (-12.18%).
- •TXG grew revenue faster over the past five years (8.74% vs 8.29% CAGR).
Metrics side by side
Valuation
| Metric | COO | TXG |
|---|---|---|
| P/E ratio | 19.26 | N/A |
| Forward P/E | 12.42 | N/A |
| P/S ratio | 2.60 | 16.60 |
| P/B ratio | 1.32 | 12.40 |
| EV / EBITDA | 14.43 | N/A |
| FCF yield | 6.16% | 1.19% |
Profitability
| Metric | COO | TXG |
|---|---|---|
| Gross margin | 63.64% | 70.03% |
| Operating margin | 12.85% | -14.33% |
| Net margin | 13.46% | -12.18% |
| ROE | 6.85% | -9.10% |
| ROIC | 4.76% | -9.57% |
Growth (annualized)
| Metric | COO | TXG |
|---|---|---|
| Revenue CAGR (5Y) | 8.29% | 8.74% |
| EPS CAGR (5Y) | -17.30% | N/A |
| FCF CAGR (5Y) | 5.21% | N/A |
| Total return CAGR (5Y) | -11.45% | -7.24% |
Frequently asked
- Which has grown faster, COO or TXG?
- Over the past five years, TXG grew revenue faster — COO at a 8.29% CAGR versus TXG at 8.74%.
- Is COO or TXG more profitable?
- COO runs the higher net margin — COO at 13.46% versus TXG at -12.18%.
- How have COO and TXG total returns compared?
- Over the past 5 years, COO delivered -11.45% and TXG delivered -7.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cooper Companies P/E ratioCooper Companies ROE10x Genomics ROECooper Companies operating margin10x Genomics operating marginCooper Companies revenue growth10x Genomics revenue growthCooper Companies free cash flow10x Genomics free cash flow
Cooper Companies & 10x Genomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.